Bayer AG and G+FLAS partner to develop enhanced tomatoes fruitnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fruitnet.com Daily Mail and Mail on Sunday newspapers.
Taste the Sun: Gene Editing Produces Vitamin D Enhanced Tomatoes genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Mar 15 2021 Read 334 Times
G+FLAS Life Sciences, has been granted a non-exclusive license agreement to access to ERS Genomics’ CRISPR/Cas9 patent portfolio. The Korean biotech (Seoul) produces research tools and reagents under ISO 13485 and ISO 9001 and is applying CRISPR PLUS technology to the development of drugs and production of CRISPR genome edited plants in a non-GMO way.
ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.
“G+FLAS is developing genome editing applications using CRISPR/Cas9 that will further expand the reach of this important gene editing tool,” said Eric Rhodes, CEO of ERS Genomics. “We are pleased to provide access to this Nobel Prize winning technology and look forward to seeing G+FLAS continue in its mission.”
G+FLAS Life Sciences is applying CRISPR technology to develop research tools and reagents ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual